Compare PLBY & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBY | ACOG |
|---|---|---|
| Founded | 1953 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 130.9M |
| IPO Year | N/A | N/A |
| Metric | PLBY | ACOG |
|---|---|---|
| Price | $1.93 | $6.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 569.1K | 96.0K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,510,000.00 | $7,427,199.00 |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $8.32 | $101.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $3.75 |
| 52 Week High | $2.44 | $11.54 |
| Indicator | PLBY | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 74.20 | 47.68 |
| Support Level | $1.57 | $5.66 |
| Resistance Level | $1.73 | $6.20 |
| Average True Range (ATR) | 0.11 | 0.47 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 97.66 | 69.59 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.